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Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia
onset to treatment, the affected brain region, and its size. The main targets of ischemic stroke therapy aim to restore tissue
perfusion in the ischemic penumbra in order to decrease the total infarct area by maintaining blood flow. Advances in research
of pathological process and pathways during acute ischemia have resulted in improvement of new treatment strategies apart from
restoring perfusion. Additionally, limiting the injury severity by manipulating the molecular mechanisms during ischemia has
become a promising approach, especially in animal research.The purpose of this article is to review completed and ongoing phases
I and II trials for the treatment of acute ischemic stroke, reviewing studies on antithrombotic, thrombolytic, neuroprotective, and
antineuroinflammatory drugs that may translate into more effective treatments.
1. Introduction
Almost 2 decades after the demonstration of a decrement and
in some instance absence of disability and the consequent
approval of r-tPA for treatment of acute ischemic stroke
(AIS), a plethora of research has been performed to better
understand not only the mechanisms involved in protecting
against AIS but also the synergy that different drugs produce
in AIS treatment. After many years, a growing number of
ischemic stroke patients lack other treatment options. A
number of phase I and phase II clinical trials designed to
develop better strategies to treat AIS are currently in progress
or completed.
The understanding of ischemic stroke pathophysiolog-
ical mechanisms is expanding. Comprehensive research in
drug development builds upon experimental ischemic stroke
models to recognize the mechanisms that underlie cerebral
ischemic injury.The lack of oxygen results in energy depriva-
tion and the ischemic cascade starts with an arterial throm-
boembolic episode. The main aim of phases I and II clinical
trials in AIS is to rescue and restore the ischemic penumbra
within a specified therapeutic window. Otherwise, the abro-
gation of energyweakens ion homeostasis and provokes a rise
in the extracellular concentration of K+, along with a decline
in extracellular concentrations of Na+ and Cl−. This anoxic
depolarization triggers not only the formation of reactive
oxygen species, glutamate release, and dysregulation in intra-
cellular Ca2+ levels, but also mitochondrial membrane col-
lapse and induction of neuroinflammation [1]. Expeditious
recanalization is mandatory to avoid an ischemic cascade
that generates neuronal tissue infarction. There are drugs
in development that aim at inducing possible neuropro-
tective factors and/or pathways, facilitating immediate reper-
fusion to alleviate the ischemic injury, blocking platelet
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Figure 1: This figure provides an overview of the cellular mechanisms activated after cerebral ischemia and their respective targets by the
different therapies (excitotoxicity and glutamate release, neuroinflammation with proinflammatory and anti-inflammatory states, etc.).
aggregation and coagulation, and degrading fibrin. Neuro-
protective agents protect ischemic neurons in the acute phase
of the ischemic stroke. We will provide an overview of the
cellular mechanisms activated after cerebral ischemia and
their respective targets in Figure 1.
2. Antithrombotic Drugs
2.1. Eptifibatide. Eptifibatide is an antiplatelet drug belonging
to the glycoprotein IIb/IIIa inhibitor class. It binds to glyco-
protein IIb/IIIa in between the IIb and IIIa arms of the acti-
vated platelet, effectively blocking the binding domain from
fibrinogen, thus inhibiting thrombi formation. It has been
studied in combination with aspirin, low molecular weight
heparin (tinzaparin), and intravenous (i.v.) r-tPA therapy in
several dosing regimens, since r-tPA alone is inadequate to
recanalize large arterial occlusions in approximately 50% of
cases. In recent years, three trials have tried to establish safety
of eptifibatide and they all kept their inclusion criteria con-
stant [2].
The CLEAR trial was designed to establish the safety
of eptifibatide in combination with r-tPA in the treatment
for AIS. The endpoint was within 36 hours, finding that
a dose escalation combination of reduced-dose r-tPA plus
eptifibatide would justify further dose-ranging trials in AIS
[3]. One group received low-dose r-tPA with eptifibatide
(75 ug/kg bolus and 0.75 ug/kg/min infusion over 2 hours)
and the other group received the standard dose of r-tPA.
The primary safety endpoint was defined as the incidence of
a symptomatic intracerebral hemorrhage (sICH) within the
period of 36 hours. Even though this trial found promising
results and was a randomized, blinded, safety trial measuring
BioMed Research International 3
low-dose r-tPA plus eptifibatide, it had a marked disparity in
age and baseline NIH Stroke Scale/Score (NIHSS) between
the combination therapy and the control groups [3]. Higher
age and NIHSS are predictors of sICH after r-tPA treatment
following AIS [4]. On the other hand, the study not only had
the EuroQoL quality of life index and Stroke-Specific Quality
of Life Scale administered at 3 months, but also has a 90-day
outcome assessed by certified investigators in the NIHSSS.
Additionally, they received standardized training regard-
ing the modified Rankin Scale (mRS), Barthel, Glasgow, and
EuroQol assessments. Furthermore, the study was not asso-
ciated with acute treatment of patients, which brings more
validity to the outcome score obtained. In light of these
points, the CLEAR trial offered insights and hope for well-
designed studies in the future in order to research the effects
of this combination using a dose escalation regimen.
Following the CLEAR trial, investigators conducted the
CLEAR-ER trial, a multicenter, double-blinded, randomized
safety study that enrolled a total of 126 AIS patients (NIHSS
score > 5) having mRS score as the primary efficacy outcome
measurement. The CLEAR-ER trial added extra points to
measure not only early patient improvement at 2, 24 hours,
and 90 days per NINDS investigators’ suggestion, but also
systemic bleeding at 7 days after therapy. This trial consol-
idated the safety of combination therapy even though mild
bleeding was found in the combination group (no interven-
tions were necessary) and the sICH rate in the r-tPA group
was greater than expected. A larger trial is necessary to
address sICH differences from CLEAR-ER when compared
to NINDS trials. However, combination treatment not only
proved to be safe when given within 3 hours of symptom
onset [5] but additionally proved to be realistic to pursue
translation with combination of eptifibatide.
After the aforementioned trials were published, a full dose
regimen trial was designed. CLEAR-FDR was a single-arm,
prospective, open-label, multisite study using 0.9mg/kg i.v.
r-tPA within 3 hours of symptom onset followed by eptifi-
batide (135𝜇g/kg bolus and 2-hour infusion at 0.75 𝜇g/kg per
minute). A repeat NIHSS score was obtained at the end of the
2-hour eptifibatide infusion and at 24 (±6) hours after r-tPA.
27 patients were enrolled in this trial, a number at least 3x
less than the amount enrolled in the CLEAR trial and almost
5x less than the CLEAR-ER trials. Importantly the single-
arm nonblinded study designs with enrollment by a single
regional stroke team are also limiting factors [6].
Aside from the limitations of the CLEAR-FDR, there is a
plan to investigate the dose response of r-tPA plus eptifibatide
via a pooled analysis of all 3 completed trials before moving
on to a phase III clinical trial.This will help estimate the vari-
ability of the trials. A demonstration of eptifibatide’s mode of
action is found in Figure 2.
2.2. Revacept. Revacept is a dimeric glycoprotein VI-fc that
blocks glycoprotein VI-dependent pathways. By interfering
with the vascular collagen site, it blocks vascular collagen
in plaques or exposed by erosion thus reducing platelet
adhesion. It was found to be safe in preclinical studies.Thirty
healthy men received a single i.v. administration of 10, 20, 40,
80, or 160mg revacept in a phase I study [7] that evaluated the
pharmacological parameters of the drug itself. Different from
the CLEAR trials, its inclusion criteria were more selective
to nonsmoking white men between the ages of 18–35, nor-
motensive, and with body weight ranging from 75 to 85 kg.
The concentration of revacept plasma was found to interrupt
aggregation beginning 2 hours after the administration of
the drug and produced significant inhibition 24 hours and
7 days following infusion with higher doses. Bleeding time
was not significantly affected, and ADP (thrombin receptor
activating peptide) dependent platelet aggregation was not
changed. The drug’s effect was longer lasting in humans than
in previously conducted animal studies, which is likely due
to the longer half-life. Among the pros and cons of the study,
revacept was safe and well tolerated in a dose dependent
pharmacologic profile.
Revacept is also being studied in conditions associated
with stroke, such as carotid stenosis, that presentswithmicro-
embolic signals (MES) [8]. MES are frequently found in
patients with acute stroke. An ongoing phase II trial using a
20-minute single dose of revacept plus antiplateletmonother-
apy (aspirin or clopidogrel) or monotherapy alone aims
to reduce MES. Figure 2 demonstrates revacept action on
decreasing platelet aggregation formation of a clot. Table 1
summarizes details of completed clinical trials testing these
antithrombotic drugs.
3. Thrombolytic Drugs
3.1. Reteplase. Reteplase is a nonglycosylated deletionmutein
of tPA, similar to alteplase but modified in order to achieve
a longer half-life (approximately 13–16 minutes), as well as
improved thrombolytic properties by binding to fibrin with
a lower affinity than alteplase.
A randomized, feasibility study using primates demon-
strated preliminary support that IA (intra-arterial) reteplase
with IV abciximab, as well as IA reteplase without IV abcix-
imab, was effective in obtaining recanalization in an intracra-
nial thrombosis model [27]. A prospective, nonrandomized,
open-label trial was conducted to evaluate the safety of an
escalating dose of reteplase in conjunctionwith i.v. abciximab
in patients with AIS (3–6 h after symptomonset).The authors
hypothesized higher rates of recanalization and improved
clinical outcomes were due to the combination of medica-
tions that lyse fibrin and prevent aggregation of platelets [9].
Patients had NIHSS scores of 4 or greater or 23 or less and
arterial occlusion demonstrated by diagnostic angiography.
Partial or complete recanalization was observed in 13 of the
20 patients. Thirteen patients demonstrated early neurolog-
ical improvement, and favorable outcome at 1 month was
observed in six patients. In this study, a combination of intra-
arterial reteplase and i.v. abciximab was safely administered
to patients with ischemic stroke presenting between 3 and 6
hours after symptom onset.
Reteplase was first studied in a primatemodel of intracra-
nial thrombosis [27], but the study was nonrandomized and
did not meet RIGOR [28] and STAIR criteria. RIGOR and
STAIR criteria are a set of recommendations for performing
better research, including the encouragement of randomiza-
tion, blinded studies, power analyses, and the like [28].
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Figure 2: The drugs eptifibatide and revacept act by decreasing platelet aggregation and further formation of a clot.
Table 1: This table summarizes the hemostatic drugs, details of clinical trials completed in AIS, route (i.v.: intravenous), phases, number of
patients enrolled, and clinical trial number.
Summary of antithrombotic drug trials
Drug Dose Time window Phase Number ofpatients
Clinical trial
number Citation
Eptifibatide
(CLEAR)
r-tPA (0.3mg/kg versus 0.45mg/kg) +
eptifibatide (75 𝜇g/kg bolus followed by
0.75 𝜇g/kg/min infusion for 2 hours) or
r-tPA (0.9mg/kg)
3 hours 1/2 10 NCT00250991 [3]
Eptifibatide
(CLEAR-ER)
0.6mg/kg r-tPA + eptifibatide (135𝜇g/kg
bolus and a 2-hour infusion at 0.75 𝜇g/kg
per minute) versus r-tPA (0.9mg/kg)
3 hours 2 126 NCT00894803 [5]
Eptifibatide
(CLEAR-FDR)
i.v. bolus of 135 𝜇g/kg eptifibatide
followed by an i.v. infusion of
0.75 𝜇g/kg/min eptifibatide for 2 hours
3 hours 2 27 NCT01977456 [6]
Revacept Single i.v. of 10, 20, 40, 80, or 160mg Laboratory,clinical exams 1 30 NCT01042964 [7]
3.2. Tenecteplase. Tenecteplase is a genetically engineered
mutant tPA which may possess some advantages over
alteplase, such as a longer half-life, more resistance to plas-
minogen activator inhibitor, more fibrin specificity, and
producing less systemic depletion of circulating fibrinogen.
These advantages lead to faster perfusion and lower inci-
dences of sICH [8]. In a New Zealand study, Parsons et al. set
out to determine whether alteplase or tenecteplase had sup-
erior outcomes. In this phase IIb trial, 75 AIS patients
received treatment in the form of alteplase (0.9mg/kg) or
tenecteplase, low dose (0.1mg/kg) or high dose (0.25mg/kg).
The baseline NIHSS scores of all patients are approximately
14 (+−2.6). Treatment was administered within 3-4 hours of
stroke onset. Outcome measures included the percentage of
perfusion of the lesion measured byMRI, clinical and neuro-
logical improvements measured by a change in NIHSS score,
and changes inmRS scores at 24 hours.Therewas a significant
improvement in the tenecteplase groups, with 79% average
reperfusion, compared to 55% in the alteplase group, as
well as 64% of tenecteplase group patients having a reduced
NIHSS score by 8 or greater, compared to 36% of the alte-
plase group. The authors conclude that phase III trials are
appropriate based on their findings [10]. A Scottish study
also tested tenecteplase versus alteplase with the endpoint
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Table 2:This table summarizes the thrombolytic drugs, details of clinical trials completed in AIS, route (i.v.: intravenous; i.a.: intra-arterial),
phases, number of patients enrolled, and clinical trial number.
Summary of thrombolytic drug trials
Drug Dose Time window Phase Number ofpatients Clinical trial number Citation
Reteplase +
abciximab
0.25mg/kg bolus of
abciximab i.v. +
0.125mcg/kg/min infusion
for 12 hours
i.a. reteplase in boluses of
0.25 units (5 minutes)
proximal to the thrombus +
incremental doses
3–6 hours after
symptom onset 1 20
FDA Protocol Number
9180 [9]
Tenecteplase
0.25mg/kg tenecteplase
0.1mg/kg tenecteplase
0.9mg/kg alteplase
6 hours after
symptom onset 2b 75
New Zealand Clinical
Trials Registry:
ACTRN12608000466347
[10]
Tenecteplase 0.25mg/kg tenecteplase0.9mg/kg alteplase
4.5 hours after
symptom onset 2 104 NCT01472926 [11]
being the percentage of penumbra salvaged seen via CT
at 24–48 hours after treatment. In a phase II, prospective,
randomized, open-label, blinded study, 104 patients were
treated with the standard dose of alteplase or high dose
(0.25mg/kg) of tenecteplase within 4.5 hours of stroke onset.
Of the 104 patients enrolled, 35 tenecteplase and 36 alteplase
patients contributed to the endpoint. No differencewas found
between the groups in salvaged penumbra, incidences of
sICH, or other adverse effects [11]. Table 2 summarizes details
of completed clinical trials testing these thrombolytic drugs.
4. Endovascular Procedure Trials
The advantages of intra-arterial treatment in AIS with ante-
rior large-vessel occlusion were proven in many random-
ized controlled trials (RCTs) and consolidated into clinical
practice. Acute large-vessel occlusions have less benefit from
r-tPA treatment. Critical time points during intra-arterial
treatment include time to angiography/perfusion imaging
and time to start revascularization with r-tPA in order to
get improved neurologic outcomes. There are 5 prospective
randomized open blinded endpoint- (PROBE-) designed
trials published between 2014 and 2015 in acute large-vessel
anterior circulation ischemia and they focus on 90-day
outcomes. According to results of these trials, endovascular
treatment groups have higher outcome scores (mRS 0–2) as a
primary endpoint. These 5 trials are the following.
ESCAPE had 315 patients studied with multiphase CTA
to determine the intracranial collateral circulation. The start
of CT to groin puncture was less than 60 minutes and time
to first reperfusion was less than 90 minutes. Different from
other RCTs, the time window in the study was 12 hours;
however the study was not powered to evaluate endovascular
therapy between 6 and 12 hours after symptom onset because
of insufficient patient number [8].
Campbell BC and colleagues published the EXTEND-
IA trial. The study was stopped early because of efficacy at
70 patients. Using advanced penumbral imaging techniques,
control patients had lowermedianNIHSS scores compared to
the endovascular group (13 versus 17, resp.).The other 4 RCTs
mentioned in this section have used ASPECT scoring for
infarct region, which was not used by the EXTEND-IA trial.
This trial focused on patients with ischemic core volume of
less than 70mL who received i.v. r-tPA within 4.5 hours’ time
window. Similar to the ESCAPE trial, internal carotid artery
or proximal MCA occluded patients were enrolled [29].
The SWIFT PRIME trial had an 88% rate of complete
reperfusion, the highest rate in comparison to the other
RCTs mentioned in this section. This finding may be asso-
ciated with exclusion of patients with extra cranial carotid
occlusion. Only EXTEND-IA and SWIFT PRIME trials have
100% of their active control groups receiving i.v. r-tPA and
comparing them to intra-arterial recanalization with i.v. r-
tPA in the study groups [30].
In October 2015, REVASCAT was published. It had the
longest median time period of 269 minutes up to recanaliza-
tion. Patients with confirmed revascularization after r-tPA
were excluded from this study. Patients who have failed treat-
ment for large-vessel occlusion after r-tPA, confirmed on
computed tomographic angiography, were the focus of end-
ovascular treatment. This trial has the lowest sICH rates
among the other 4 endovascular trials, further supporting the
efficacy of endovascular treatment up to 8 hours; however the
study was terminated before completing planned enrollment
[31].
A 2015 meta-analysis sought to compare outcomes in the
form of functional independence (mRS scores between 0 and
2 at 90 days) in 8 clinical trial studies, including SYNTHESIS,
MR RESCUE, MR CLEAN, ESCAPE, EXTEND-IA, and
REVASCAT. Endovascular therapy treatment patients had
better outcomes across the board. There were no significant
differences in mortality or incidence of sICH between endo-
vascular therapy groups andmedication only groups.Authors
concluded that the best course of action is a treatment that
combines standard medical treatments with endovascular
therapy for best outcomes for qualifying patients [32].
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5. Neuroprotection
5.1. Lovastatin. Beside cholesterol reducing effects, statins
are considered to have favorable impact on blood brain bar-
rier, oxidative stress, cerebral blood flow, and inflammation
according to previous studies. Experimental studies showed
several statins have neuroprotective effects on neuronal
injury and infarct size in rodent models of AIS when given
both before and after AIS [33, 34]. However, a meta-analysis
in 2011 by Squizzato et al. demonstrated that in 8 randomized
clinical trials involving 625 participants statin treatment did
not reduce all-cause mortality compared with placebo or no
treatment in the 431 patients enrolled in 7 out of the 8 studies.
This was explained as due to inadequate data [31].
The Neuroprotection with Statin Therapy for Acute
Recovery Trial (NeuSTART) is a nonrandomized, single
group assignment, phase I B dose-escalation study focused on
testing the hypothesis that short-term statin therapy at maxi-
mally effective doses provides neuroprotection based on ani-
mal studies. In this trial AIS patients were treated within 24
hours of symptom onset. The maximum tolerated lovastatin
dose was 8mg/kg/day, which is a higher dose than currently
approved by the FDA, and they found 13% toxicity. No clinical
liver disease, myopathy, or creatine phosphokinase elevations
were reported. This trial showed an appropriate treatment
period of 3 days after an AIS for that dose. They found
a significant decrease in TNF-𝛼 receptor 1 (TNFR1) levels
associated with dose increase but no effects on CRP, IL-6,
or TNF levels. In addition, no significant dose-related effect
on platelet aggregation was detected. The limitations of this
trial include insufficient patient number and no neurological
outcome reported during dose escalation. On the other hand,
it is encouraging to see that a dose higher than the current
oralmaximumwas toleratedwith low toxicity.Thus, this dose
could be used in future placebo-controlled randomized trials
for various outcomes [35].
Researchers are recruiting individuals for a phase II clini-
cal trial with low and high dose lovastatin comparing to
placebo within 24 hours of symptom onset.The inclusion cri-
teria for this trial differ from the prior trial in that patients will
receive both standard dose i.v. t-PA and/or mechanical inter-
ventional procedures in their respective groups. The study
will focus primarily on musculoskeletal and hepatic toxicity
with a 3-month follow-up period. Secondary targets are neu-
rological outcomes and effects on inflammatory markers [14,
35].
5.2. Donepezil. Donepezil is a reversible, selective acetyl-
cholinesterase inhibitor broadly used in the treatment of
Alzheimer’s dementia [36]. Enhancement of the cholinergic
system showed beneficial effects in trials of chronic stroke
[37, 38] and poststroke recovery [39–42] and in experimental
stroke models [43]. These results led to the open-label study
conducted by the Mayo Acute Stroke Trial for Enhancing
Recovery (MASTER) StudyGroup.Thirty-three patientswith
AIS were treated with donepezil within 24 hours after event.
Donepezil was demonstrated to be safe and tolerated at an ini-
tial dose of 5mg daily for the first 4 weeks; then it was
increased to 10mg per day. Neurologic, cognitive, functional,
and psychological outcomes 90 days after stroke with done-
pezil treatment compared to the National Institutes of Health
Stroke Scale (NINDS) r-tPA trial data showed a tendency
for favorable outcomes [44]. The evidence was satisfying
enough for this research group to plan further investigation
of donepezil in AIS management in a randomized study.
Limitations to the MASTER Study include the fact that
it was single-armed and open-label study conducted with 33
patients and only 76% of the enrolled patients completed
the 90-day treatment. There was no concurrent control
group, and instead the results were compared to data from
the National Institute of Neurological Disorders and Stroke
(NINDS) r-tPA trial. Patients with probability of AIS were
also included.The null hypothesis with the preset level of sig-
nificance (alpha = 0.10) for continuation in a randomized
controlled study was just barely met. Table 3 provides details
about clinical trials investigating the neuroprotective drugs.
6. Neurogenesis
6.1. Granulocyte Colony-Stimulating Factor (G-CSF). Granu-
locyte colony-stimulating factor (G-CSF) is a growth factor
cytokine and hormone that stimulates the bone marrow
to produce granulocytes and stem cells. Genetically engi-
neered recombinant human G-CSF (such as leucostim and
filgrastim) is frequently used in the treatment of neutro-
penia associated with chemotherapy or bone marrow trans-
plantation. Their physicochemical characteristics and spe-
cific biological activity are equal. Preclinical results from
numerous studies in stroke models statistically confirmed
that recombinant G-CSF has both neuroprotective and neu-
roreparative effects, activating antiapoptotic, antioxidative,
and anti-inflammatory signaling pathways, and stimulating
angiogenesis [45]. For further translation into the clinical
setting, several safety and feasibility studies were conducted
using different dosages and different recombinant G-CSF
analogs as additional treatment in AIS patients.
A Russian research group evaluated leucostim effects on
blood cell count after AI and specifically focused on leuko-
cytes and progenitor stem cells. In their randomized con-
trolled study leucostim was given s.c. 10mg/kg/day in addi-
tion to conservative treatment. They concluded treatment
within 48 hours after AIS for 5 days to be safe, with no signi-
ficant difference in the outcome (NIHSS, BI, Glasgow Out-
come Scale) compared to the control group shown [25]. The
study group was small with only 20 patients enrolled, and
only six patients completed the full G-CSF treatment. The
treatment was given in addition to conventional therapy, but
patients with thrombolysis were excluded from this study.
Also, there was no placebo given to the control group. For the
safety analysis all patients were included, but for the efficacy
analysis only the patients who completed the 180-day follow-
up were included.
A Chinese randomized controlled trial was conducted
on ten patients with middle cerebral artery infarction. Seven
were treated with filgrastim 15 𝜇g/kg/d s.c. for 5 days. Out-
come was assessed with the National Institute of Health
Stroke Scale (NIHSS), European Stroke Scale (ESS), Euro-
pean Stroke Scale Motor Subscale (EMS), and Barthel Index
BioMed Research International 7
Table 3: This table summarizes neuroprotective drugs, details of clinical trials completed in AIS, route (i.v.: intravenous; p.o.: per-oral),
phases, number of patients enrolled, and clinical trial number.
Summary of neuroprotective drug trials
Drug Dose Time window Phase Number ofpatients
Clinical trial
number Citation
GSK249320 i.v. escalation cohorts1, 5, and 15mg/kg 24–72 hours 2 42 NCT00833989 [12]
GSK249320
i.v. escalation doses of
0.04, 0.4, 1.2, 3.5, 10,
and 25mg/kg
Healthy
volunteers 1 47 NCT00622609 [13]
Lovastatin 1, 3, 6, 8, and 10mg/kgper day for 3 days 24 hours 1 33 NCT00243880 [14]
Donepezil
5mg/day p.o. for 30
days, increased to
10mg/day for 60 days
≤24 hours 2a 33 NCT00805792 [15]
(BI). Initial treatment within a window of 7 days demon-
strated beneficial effects on outcome compared to nontreated
patients, while G-CSF administration within 24 hours after
stroke was superior. Furthermore, every patient underwent
MRI and PET at the 12-month follow-up, showing increased
metabolic activity in the peri-infarction area after G-CSF
treatment [21]. There was no mention of whether throm-
bolysis was performed in these patients. This study did not
prespecify a baseline infarction volume.
In Germany, 20 patients with AIS were enrolled in
an open-label dose-escalation study and treated with three
dosages of filgrastim s.c. (2.5, 5, or 10 𝜇g/kg/daily for 5 days)
within 12 hours of onset [46]. Full standard care was given,
including thrombolysis with i.v. r-tPA (0.9mg/kg) within
3 hours of stroke. Although the inclusion criteria specified
ischemia in the middle cerebral artery (MCA) territory, one
patient with anterior cerebral infarction and two patients
with vertebrobasilar territory infarction were regarded as a
minor protocol violation and not excluded. Also, because the
age window was broad (age over 18 years), two patients in
their thirties were included. In small study groups this can
have a big impact. Infarction area was evaluated with voxel-
guidedmorphometry and neurological outcomewas assessed
(NIHSS, mRS, BI). Neurophysiological testing showed a
time-dependent improvement, but there was no comparison
to a control group. Four patientswith adverse side eventswere
suggested to be unlikely related to G-CSF.
In a Japanese prospective phase I study, filgrastim was
given to 18 patients in three doses i.v. (150, 300, or 450𝜇g/kg/
day) at two time points after event (24 hours or at 7 days).The
lower dosages produced no increase in leukocytes and were
safe and well tolerated. Past 90 days, neurological outcomes
(NIHSS, mRS, BI) were improved in those with G-CSF
treatment within 24 hours compared to treatment starting 7
days later [22].This study is limited due to the small numbers
of patients (𝑛 = 3 for each group and time point). The aim
to evaluate two treatment windows and different dosages in a
single phase I study with only 18 enrolled patients may have
been too optimistic. Additionally, the conventional stroke
therapy regimen such as antiplatelet or anticoagulant agents
in the acute phase differed from the subacute phase group.
Two German research groups conducted twomulticenter
trials with large cohorts. The first was the AXIS-2 trial that
enrolled 44 patients in a randomized, placebo-controlled
dose-escalation study analyzing four i.v. dosages of filgrastim
over 3 days (30, 90, 135, and 180 𝜇g/kg cumulative doses).The
treatment window was 12 hours after stroke [23]. Elevation of
leukocyte counts never reached the prespecified level for ter-
mination and decreased spontaneously at the end of therapy;
however, no harmful effects were observed at the 3-month
follow-up. These results led to the subsequent multicenter,
randomized, and placebo-controlled trial with a cohort of 324
treated patients. Filgrastim was administered within 9 hours
after the stroke event in a cumulative dose of 135 𝜇g/kg i.v.
over 72 hours to patients with medium and large ischemic
infarctions in MCA territory. A tendency for radiologically
reduced infarction volume was observed, but the study failed
to prove significant beneficial effects in outcome (NIHSS,
mRS, BI) after 3 months [24], despite promising preclinical
and clinical data. These results demonstrate the challenges
in translating findings from the animal laboratory to clinical
stroke patients.
In summary, there is no clinical trial data published to
date that shows significant successful effects of G-CSF treat-
ment in a large cohort of stroke patients. Leukocyte counts
were temporarily increased during treatment, yet no harmful
effects were observed in any trial. Mobilized hematopoietic
cells in peripheral blood were elevated after recombinant G-
CSF treatment, proving effects of treatment. Early adminis-
tration of G-CSF treatment of AIS within 12 to 24 hours after
onset has only shown a trend towards beneficial effect on
outcome.
7. Neuroinflammation
7.1. SA4503. Sigma receptors are involved in several central
nervous system (CNS) disorders. More specifically, sigma-
1 receptors found in the endoplasmic reticulum are binding
sites which may have an effect on neurotransmitter systems
via calcium signaling. Cutamesine is a ligand selective for this
receptor andmay oversee some neuroprotective effects in the
framework of neurodegenerative diseases [47]. A growing
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body of evidence indicates the involvement of sigma-1
receptors in the mechanisms of various therapeutic drugs;
examples include donepezil and neurosteroids [48].
Previous studies prove that IL-1𝛽, TNF-𝛼, and IFN-𝛾 lev-
els are elevated in the ischemic hemisphere following stroke.
Sig-1R activation reduces microglia activity and release of
TNF-𝛼, IL-10, and nitric oxide in lipopolysaccharide acti-
vated cells. It also helps to stabilize some intracellular proteins
in response to cellular stress and induces bcl-2 in reactive oxy-
gen species dependent apoptosis [49]. Ruscher and colleagues
demonstrated that treatment with SA4503 in a rat MCAO
model had no effect on proinflammatory cytokines in the
infarct core or peri-infarct region but resulted in a significant
increase in Iba1 expression in the infarct core [50].
Urfer and colleagues conducted a multicenter, random-
ized, double-blind, placebo-controlled phase II study with 60
patients giving once daily low and high dose oral cutamesine
treatment 48–72 hours after AIS for 28 days. It was reported
that the average time from stroke onset to starting treatment
was 60 hours. At the end of the 28th and 56th day there was
no significant neurological improvement between low and
high dose regimens compared to the placebo group.However,
patients with a baseline NIHSS score of ≥7 and 9 showed a
statistically significant difference between the 3mg/d cutame-
sine group and placebo from baseline total NIHSS at the
end of treatment [49]. The authors pointed out that patients
treated with 3mg/d cutamesine had a better 10-minute walk
test compared to placebo at the 28th and 56th day but with no
statistically significant difference, even though these patients
received similar hours of daily rehabilitation therapy. In this
clinical trial, treatment was started in the subacute phase
of stroke. Consequently, the patient population included
mostly neurologically stable patients compared to those in the
acute phase. Treatment was applied long after thrombolytic
therapy; thus patients had higher baseline neurological scores
before initiation of oral cutamesine. This likely explains why
oral cutamesine treatment has better outcomes in patients
with higher baseline neurologic score.The results of this trial
might support the use of cutamesine as a supportive drug
along with physical therapy in patients who have moderate
neurological status after AIS.
In the following sections, we will discuss different groups
of neuroprotective agents according to their mechanism of
action such as excitotoxicity and oxidative stress reduc-
tion.
8. Excitotoxicity
8.1. Caffeinol. Caffeinol includes caffeine plus ethanol and
acts through central adenosine, gamma-aminobutyric acid
(GABA) A, and N-methyl-D-aspartate (NMDA) receptors
[51]. Belayev and colleagues applied caffeinol in ischemic rats
starting at 15 minutes after reperfusion with a 2.5-hour infu-
sion. They reported a significant decrease in cortical infarct
volumes and an increase in neurological scores; however,
no significant difference was found on subcortical infarct
volumes and brain edema [52]. Zhao and colleagues applied
caffeinol to rats up to 2-3 h after the onset of transient focal
ischemia and found a dramatic decrease in cortical infarct
volume [53].This in vivo excitotoxicitymodel based on intra-
cortical infusion of NMDA and a model of reversible focal
ischemia demonstrated NMDA receptor inhibition as one of
the possible mechanisms of caffeinol anti-ischemic activity.
They also emphasized the antiexcitotoxic effect of caffeinol
was not as potent as its anti-ischemic effect. Conversely, in
a rabbit small clot embolic stroke model, caffeinol treat-
ment was administered as an infusion or as multiple bolus
injections but no improvement in behavioral rating scores
following an embolic stroke was detected [54]. Lapchak and
colleagues explained that the conflict regarding rat studies
is due to the fact that ischemic lesion in this rat model not
only is restricted to the cerebral cortex but also includes sub-
cortical regions.This observation is compatiblewith the study
by Belayev and colleagues, which found no caffeinol neuro-
protective effects on subcortical infarct volumes. In the same
study, Lapchak and colleagues combined caffeinol admin-
istration with low-dose t-PA. However, this combination
reduced neurologic scores and raised the incidence of intrac-
erebral hemorrhage, although not significantly.
Martin-Schild and colleagues designed a phase I, non-
randomized, single group assignment trial with 20 patients
and aimed to investigate if caffeinol (caffeine 8-9mg/kg +
ethanol 0.4 g/kg IV X 2 h, started 4 hours after the onset of
symptoms) and hypothermia (starting 5 hours after symptom
onset, continued for 24 hours reaching a target temperature
between 33 and 35∘C, and followed by 12 hours of rewarming)
could be administered safely together with t-PA treatment in
first 3-4 h of acute ischemic stroke. Neurologic improvement
in NHISS scores and adverse events related to t-PA was not
higher than the expected rate. Main weaknesses of the trial
include inadequate number of patients, no placebo group,
and only about 1/2–2/3 of the patients being reported to have
reached the targeted post-caffeinol caffeine and ethanol levels
used in previous rodent studies [17].
9. Oxidative Stress and Cytoprotection
9.1. Edaravone. Edaravone (3-methyl-1-phenyl-2-pyrazolin-
5-one) is a radical scavenger that inhibits nonenzymatic lipid
peroxidation and lipoxygenase pathways. It has neuroprotec-
tive roles against ischemia or reperfusion-induced vascular
endothelial cell injury as well as against delayed neuronal
death, brain edema, and neurological deficits. Edaravone was
shown to avoid extravasation of r-tPA administered in an
ischemic stroke rat model thereby reducing the incidence
of hemorrhagic transformation. In an observational study,
edaravone treatment was found to have a low frequency of
hemorrhagic transformation and mortality. In a propensity-
matched analysis study, Wada and colleagues reported that
combining r-tPA treatment with edaravone improved mRS
scores at discharge after acute ischemic stroke. No significant
effect was found on 7-day mortality, hemorrhagic transfor-
mation, or length of hospital stay [55].
An ongoing phase II clinical trial (NCT02430350) is
focusing on different doses of edaravone injection for 14 days
following AIS. The investigators are evaluating neurological
outcomes, cognitive assessment, and safety of the drug out to
90 days. In Japan a regimen combining r-tPA + MCI-186 has
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been used with 30mg i.v. MCI-186 over 30 minutes twice per
a day for 14 days following AIS.
Kaste and colleagues conducted a phase II multicen-
ter, double-blinded, placebo-controlled clinical trial in 36
ischemic stroke patients. Two different doses at 24 h after
stroke were planned. Various acute adverse effects were
reported in 88.9%. Hypertension was found to be the most
frequent hemodynamic adverse effect in both groups. Atrial
fibrillation was more frequent in high dose treatment group
but there was no significant difference for other adverse
effects between the 2 dose regimens. Both dosing regimens
raised the plasma concentration to a plateau within 24 hours;
however, this trial was lacking in detailed pharmacokinetic
parameters. The authors analyzed neurological impairments
in the full analysis population ofwhich all patients had a base-
line NIHSS score of 3–15. There were no significant dif-
ferences in neurological improvement results between the
placebo group and the 2 dosing regimens at 72 h, 120 h, 31 and
87 days [18]. The main limitation of this trial is inadequate
patient enrollment compared to 252 patients that enrolled
in the Japanese r-tPA + MCI-186 study. Furthermore, since
Kaste and colleagues reported no significant acute neurologic
improvement at the end of the treatment (72 h) after stroke,
two possible perspectives can be considered. First, acute
MCI-186 infusion might have better clinical effects in the
chronic period (more than 3 months) after stroke and it
deserves investigation. Second, researching the effects of long
termMCI-186 treatment following acute ischemic stroke (14-
day treatment) as done in the Japanese drug approval protocol
seems warranted. Furthermore, due to high acute adverse
effects, oral treatment regimens might be more feasible than
i.v. infusion in clinical trials.
9.2. Glyburide (RP-1127). Glyburide (RP-1127), also known
as Glibenclamide (Gbc), is an antidiabetic drug in the class
of sulfonylureas and functions by blocking either adenosine
triphosphate- (ATP-) sensitive K+ channels and/or sulfony-
lurea receptor 1 (SUR1) in various experimental ischemic
models [56]. KATP channels are rapidly activated in response
to an increase of intracellular ADP/hypoxia causing K+ efflux
that leads to inflammation and oxidative stress. Blockade of
sulfonylurea receptorswith lowdoses ofGbc reduced cerebral
edema and infarct volume and decreased mortality by 50%
in ischemic stroke rat models. Sulfonylurea receptors are
associated with the astroglial NCCa-ATP channel [57] and
microglial KATP channel. Abdallah and colleagues exhibited
Gbc effects on diminishing neutrophil recruitment, recov-
ering prooxidant/antioxidant balance, decreasing inflamma-
tory mediators, increasing IL-10, and mitigating reperfusion-
induced hypoglycemia in a study usingGbc pretreatment and
Gbc 10 minutes before ischemia-reperfusion [58].
Sheth and colleagues conducted an open-label, single
group assignment, phase II trial (GAMES-Pilot) in 10 severe
anterior circulation ischemic stroke patients, 90% of whom
had high NIHSS scores and received r-tPA. They aimed to
investigate feasibility and tolerability of RP-1127 in this set-
ting.The study results included reduced hemispheric volume,
hemorrhagic transformation, lesion growth, and mortality,
along with improved neurological outcomes. Limitations to
this trial include small study size and no placebo control
group [59]. The same group conducted a retrospective, case-
control clinical trial using patients from the GAMES-Pilot
trial, using matched control cohorts who were in two differ-
ent stroke protocols at a single institute.They aimed to evalu-
ate the effect of i.v. Gbc on vasogenic and cytotoxic brain
edema with MMP-9. No difference between apparent diffu-
sion coefficient (maps sensitive to cytotoxic edema in early
stages of infarction) values at day one was found, but lower
MMP-9 levels were detected in i.v. Gbc patients [59]. As the
study highlighted, the main disadvantages in this trial are
the insufficient number of patients with different baseline
data between control groups and timing heterogeneity for
MRI and blood sampling between groups. In addition, the
GAMES-Pilot study included only large hemispheric infarc-
tion and it is challenging to adapt these results to ischemic
stroke patients. On the other hand, it is important to empha-
size that i.v. Gbc treatment was associated with lower hemor-
rhagic transformation and MMP-9 levels.
A recent and more promising GAMES-RP trial with the
same research group was designed as a randomized, pro-
spective, placebo-controlled, double-blind phase II trial of
RP-1127 in subjects with a severe anterior circulation ischemic
stroke. Important criteria for inclusion are patients with r-tPA
treatment and 10-hour treatment window for i.v. Glyburide
injection.The author’s rationale was due to the GAMES-Pilot
study data that revealed that RP-1127 had positive effects up
to 10 h.The pivotal objective of GAMES-RP study is to speci-
fically purpose patients who are prone to malignant edema
after ischemic stroke.
9.3. 3K3A-APC. Activated protein C (APC) is derived from
plasma protease zymogen, provides neuroprotection, and has
antithrombotic and anti-inflammatory effects. APC stimu-
lates multiple cytoprotective pathways via the protease acti-
vated receptor-1 (PAR-1) reducing ischemia induced injury
[60]. 3K3A-APC is a recombinant variant of humanAPC that
was designed to preserve activity at PAR-1, such as cell sig-
naling actions, but with reduced anticoagulation. Although
reduced anticoagulation may seem counterintuitive, when
APC was used for the treatment of sepsis, serious bleeding
was a common side effect. Thus, a modified APC (3K3A-
APC) was created to address this issue. A phase I trial [26, 61]
characterized pharmacokinetics and anticoagulation effects
demonstrating that this protein was well tolerated at multiple
doses as high as 540 g/kg 2x daily for 3 days. In addition, it also
confirmed the drug had minimal coagulopathy effects. The
study established tolerability and safety of the 540mg/kg dose
as only nonserious side effects were observed. 3K3A-APC
shows synergistic efficacy in combination with r-tPA, with
hemorrhage rates reduced after r-tPA treatment in combina-
tion [62–64]. However, when used in combination, 3K3A-
APC shows no effect on r-tPA lytic effect [65].
3K3A-APC was shown to protect aging female mice
as well as comorbid spontaneously hypertensive rats from
ischemic stroke, as well as to extend the therapeutic window
of r-tPA [61]. While all of this data is reassuring, there still
remains uncertainty regarding whether the drug will work
in humans, as there is no valid guide to translate effective
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serum concentrations in rodents to dosing in humans, as
highlighted by the authors. In the past, many neuroprotectant
agents have failed partly because serum concentrations were
significantly lower in subjects than in the successful animal
studies. It is reassuring that the maximally tolerated dose in
healthy volunteers is well above the dose (200 g/kg) shown to
be maximally protective in animals [66, 67].
There is currently an ongoing phase II trial, RHAPSODY,
to evaluate the safety and efficacy of 3K3A-APC in multiple
intravenous doses. This double-blinded, randomized study
aims to measure adverse events that meet dose limiting toxi-
city, as well as the maximum observed plasma concentration
of the target drug. Participants suffering from ischemic stroke
will be treated with 3K3A-APC or a placebo, as well as either
r-tPA or mechanical thrombectomy, or both treatments. The
RHAPSODY trial is scheduled to be completed inMarch 2017
(NCT02222714).
Further clinical development should include a tolerability
study in stroke subjects [26, 61]. In summary, the molecule
demonstrates it was engineered for minimal coagulopathy.
Table 4 provides details about clinical trials investigating
the drugs.
10. Conclusion
In this review, a number of clinical trials resulting in positive
findings were identified. These hold the potential for future
phase 3 studies in the area of AIS. The combination of
eptifibatide with r-tPA has brought great hope to the future
treatment of AIS. The “CLEAR” trials proved safety and
tolerability up to 36 hours with dose escalation. Studies
on reteplase with abciximab provided optimistic results
regarding the possibility of increasing reperfusion after AIS.
Furthermore, reteplase has joined the list of drugs being
considered for use in the clinical setting. There is potential
for synergy of drugs that inhibit platelet adhesion to the
subendothelium and thrombolytic agents thereby improving
clot degradation.
A very common issue is the challenge of enrolling a
sufficient number of representative patients with comparable
characteristics. Therefore, the results represent more a pre-
liminary estimation than a representative evaluation. Some
trials lack a control group. As in many stroke trials NIHSS,
mRS, and BI evaluation does not necessarily correspond with
infarction volume and overall tissue damage. Furthermore,
NIHSS scores at presentation should be similar in each arm,
as it is amajor contributor and predictor of clinical outcomes.
When considering the results of the phase I/II clinical
trials discussed in this review, many challenging unanswered
questions still remain. Specific drugs offer higher potential for
clinical translation, including revacept and eptifibatide. The
pursuit of a better therapy and continuation of preclinical and
clinical trials is imperative in order to reach a new level of
treatment options for acute ischemic stroke. Future phase 3
clinical trials will be observed closely to determine which of
these therapies hold the key to advances in treating AIS.
It is important to highlight that neuroprotective treatment
strategies after acute ischemic stroke should focus on the pro-
gression of destructive molecular and biochemical cascades
following cerebral hypoperfusion and anaerobic glycolysis.
The aims of these neuroprotective approaches are to pre-
vent ischemic brain injury from progressing into infarction.
The ischemic penumbra is a conceivably recoverable region
around the ischemic core where collateral cerebral blood
flow supports neuronal perfusion. Thrombolytic and endo-
vascular treatment provides reperfusion and attenuates the
development of irreversible neuronal injury in penumbral
region. Ischemic cascades have various spots in which its
inhibition might increase the effectiveness of perfusion with
thrombolytic and endovascular strategies. Time window is
one of the crucial factors determining the treatment effi-
cacy, particularly in thrombolytic and antithrombotic drugs.
When eptifibatide was applied within 3 hours and reteplase
+ abciximab within 3 to 6 hours, neurological improvement
was reported. Similarly time windows in recent endovascular
clinical trials treatments are from 6 to 12 hours.
Possible pathophysiological steps that can bemanipulated
following anaerobic glycolysis are ionic imbalance, oxidative
effects of free radicals, excitotoxicity, neuroinflammation, and
apoptosis. The neuroprotective drugs are generally applied
24 to 72 hours after ischemic stroke onset and have favor-
able outcome in trials. This is due to the fact that their
mechanism does not depend on restoring cerebral perfusion
and therefore differs from antithrombotic and fibrinolytic
drugs. Thus, encouraging treatment strategies should focus
on combination therapies with fibrinolytic drugs in early
stroke and neuroprotective drugs in 24 to 72 hours.
There is growing experimental evidence regarding the
association between ischemic brain injury, neuroinflamma-
tion, and endogenous neurogenesis during the recovery
period. Ischemic injury stimulates neurogenesis in the sub-
ventricular zone and subgranular layer of dentate gyrus. For
that reason, the recombinant form of G-CSF, by stimulating
neurogenesis, is suggested to be a future additional treatment
to standard of care.
Given the plethora of information from phase I and phase
II clinical trials in acute ischemic stroke, it is imperative
that researchers do not dismay over negative results of these
clinical trials but keep looking forward to more designs and
new medications used in other areas of medicine that may
benefit the brain via their mechanism of action. This will not
only improve health and survival but also improve neurolog-
ical outcome following AIS. In addition, future clinical trials
should include a larger number of patients, different time
windows, fulfillment of the planned enrollment, multicenter
design, application of r-tPA, use of advanced neuroimaging
techniques to target penumbra, and a clear separation of
patients before treatment according to neurological scores for
accurate correlation between treatment and prior neurologic
severity. The STAIR and RIGOR criteria should be followed.
It is well known in the literature that drug develop-
ment strategies for acute ischemic stroke have failed due to
incompatible preclinical models and issues with designing of
clinical trials [68].Themain difficulties of drug improvement
in acute ischemic stroke trials are the restricted therapeutic
window before reperfusion of salvageable brain tissue, clin-
ical misclassification, and inadequate sample size [69]. The
evolving of neuroprotective agents is generally sustained by in
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Table 4: This table summarizes the different drugs, details of clinical trials completed in AIS, route (i.v.: intravenous; s.c.: subcutaneous),
phases, n/a: not available, number of patients enrolled, and clinical trial number.
Summary of trials for neuroinflammation, excitotoxicity, and oxidative stress drugs
Drug Dose Time window Phase
Number
of
patients
Clinical trial
number Citation
SA4503
Oral treatment of 1mg/d
and 3mg/d for a period of
28 days
48 to 72 hours 2 60 NCT00639249 [16]
Caffeinol +
hypothermia
Infusion of caffeinol
(9mg/kg caffeine + 0.4 g/kg
ethanol) over 2 hours
4 hours 1/2 30 NCT00299416 [17]
Edaravone
12.5mg/37.5mg/62.5mg
one dose every 12 hours, for
period of 14 days
24 hours 2 400 NCT01929096 [18]
RP-1127
3mg/day i.v. 3 boluses
followed by infusion for 72
hours
≤10 hours 2 10 NCT01268683 [19]
RP-1127
i.v. bolus followed by
continuous infusion for 72
hours
4.5 hours 2 34 NCT01132703 [20]
Filgrastim s.c. 15𝜇g/kg per day for 5days 7 days n/a 10 n/a [21]
Filgrastim
3 i.v. doses (150, 300, or
450 𝜇g/body/day, divided
into 2 doses for 5 days)
24 hours and 7
days 1 18 n/a [22]
AX200
(G-CSF)
4 i.v. doses, total cumulative
doses of 30–180 𝜇g/kg over
the course of 3 days
<12 hours 2a 44 NCT00132470 [23]
AX200
(filgrastim) 135 𝜇g/kg i.v. over 72 hours 9 hours 2 328 NCT00927836 [24]
Leucostim 10mg/kg s.c. per day for 5days ≤48 hours 2 20 NCT00901381 [25]
3K3A-APC
3K3A-APC at 6, 30, 90, 180,
360, 540, or 720 g/kg and 5
doses: 90, 180, 360, or
540 g/kg every 12 hours
after safety of the first. g/kg
every 12 hours after safety
of the first
Measurements at
12 and 24 hours 1 64 NCT01660230 [26]
3K3A-APC
3K3A-APC at 120 ug/kg,
240 ug/kg, 360 ug/kg, or
540 ug/kg
Measurements at
12 hours for up to 5
doses
2 100 NCT02222714 Not yetpublished
vivo or in vitro data. Reasons of these agents success in animal
studies but failure in clinical trials are due to planning and
analysis problems in experimental data as well as not effective
and broad usage of new neuroimaging modalities in animal
studies [70]. Thus, infarct volume declines or neurologic
improvements in animal models cannot be reflected into
clinical trials outcomes. In order to increase the effectiveness
of experimental designs researchers need to integrate the
reperfusion treatments and neuroprotective agents together
in animal studies with adequate sample size and more spe-
cific tissue targeting [71]. Promising future strategies might
involve focusing on neurovascular unit injury, response
of pericytes, and recruitment of peripheral immune cells
following ischemic stroke [72].
Before starting a clinical trial, it is imperative to know
the estimate number of patients and the eligible ones at
each site. Main limitations for a clinical trial are age, stroke
severity, time to start treatment as well as placebo control,
double blind manner, and randomization mechanisms. In
addition, it is time consuming, challenging, and expensive
task to design, implement, and conduct clinical trials for acute
ischemic stroke. For these reasons, organization of clinical
trial and safety concerns is addressed to ensure the design and
performance of optimal trials to safely evaluate the drug being
tested. During the process of drug development, ensure that
regulatory guidelines are met and the results of these studies
should be revealed to the public. Thus, following Stroke
Therapy Academic Industry Roundtable (STAIR) guidelines
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would guarantee optimal development of new acute stroke
therapies follow specific recommendations that would sup-
port the translation frombench side to clinical situations [73].
All these measures would decrease pitfalls and ensure rando-
mization and appropriate sample size and transparent report-
ing [74].
Over the next five years, research in therapies for acute
ischemic stroke will grow along with our understanding of
the various pathways in which neural injury as well as neural
protection occurs. We predict that r-tPA will not be the only
treatment option available for patients presenting with acute
ischemic stroke.
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